MOC-31

Product Description

MOC-31 antibody, also known as Epithelial Specific Antigen/Ep-CAM, recognizes an epithelial-associated, glycoprotein located on the cell membrane surface and in the cytoplasm of virtually all epithelial cells. It is not present in most squamous epithelia, hepatocytes, renal proximal tubular cells, gastric parietal cells and myoepithelial cells. MOC-31 may be used in a panel of antibodies as a negative marker for mesothelioma, or lung adenocarcinoma. Studies have shown that MOC-31 is useful in differentiating tumors of unknown origin in liver cancers and distinguishing cholangiocarcinoma from hepatocellular carcinomas.

Specifications

1. Morrison C, Marsh W Jr, Frankel WL. A comparison of CD10 to pCEA, MOC-31, and hepatocyte for the distinction of malignant tumors in the liver. Mod Pathol. 2002 Dec;15(12):1279-87.
2. Proca DM, Niemann TH, Porcell AI, DeYoung BR. MOC31 immunoreactivity in primary and metastatic carcinoma of the liver. Report of findings and review of other utilized markers. Appl Immunohistochem Mol Morphol. 2000 Jun;8(2):120-5.
3. Pai RK, West RB. MOC-31 exhibits superior reactivity compared with Ber-EP4 in invasive lobular and ductal carcinoma of the breast: a tissue microarray study. Appl Immunohistochem Mol Morphol. 2009 May; 17(3):202-6.
4. Nelson G. Ordonez, MD. Value of the MOC-31 monoclonal antibody in differentiating epithelial pleural mesothelioma from lung adenocarcinoma. Human Pathol. 1998 Feb; 29(2): 166-169.
5. Center for Disease Control Manual. Guide: Safety Management, NO. CDC-22, Atlanta, GA. April 30, 1976 “Decontamination of Laboratory Sink Drains to Remove Azide Salts.”
6. National Committee for Clinical Laboratory Standards (NCCLS). Protection of laboratory workers from infectious diseases transmitted by blood and tissue; proposed guideline. Villanova, PA 1991;7(9). Order code M29-P.